{Reference Type}: Journal Article
{Title}: Key considerations in navigating ticagrelor's reported effect on heparin-induced thrombocytopenia functional assays in a landscape of limited data.
{Author}: Salman G;Johannesmeyer HJ;Breen MJ;
{Journal}: Am J Health Syst Pharm
{Volume}: 81
{Issue}: 12
{Year}: 2024 Jun 11
{Factor}: 2.98
{DOI}: 10.1093/ajhp/zxae040
{Abstract}: <B>OBJECTIVE: </B>This article discusses key considerations regarding ticagrelor's reported effect on heparin-induced thrombocytopenia functional assays, such as literature gaps and possible management strategies.<BR><B>CONCLUSIONS: </B>Limited data indicate that ticagrelor may induce false-negative results in functional assays used in the diagnosis of heparin-induced thrombocytopenia. False-negative functional assays for heparin-induced thrombocytopenia could have catastrophic consequences. The manufacturer labeling of ticagrelor now includes a warning for this potential drug-laboratory interaction. This article suggests areas that would benefit from further research and strategies in navigating this possible interaction.<BR><B>CONCLUSIONS: </B>Clinicians should exercise caution when evaluating functional assays for heparin-induced thrombocytopenia in patients receiving ticagrelor. This article offers suggestions for future areas of research and potential management strategies.